These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 15670245

  • 1. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
    Konopnicki D, De Wit S, Poll B, Crommentuyn K, Huitema A, Clumeck N.
    HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Jan; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 3. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C.
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [Abstract] [Full Text] [Related]

  • 5. Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring.
    Wasmuth JC, Rodermann E, Voigt E, Vogel M, Lauenroth-Mai E, Jessen A, Burger D, Rockstroh JK.
    Eur J Med Res; 2007 Jul 26; 12(7):289-94. PubMed ID: 17933700
    [Abstract] [Full Text] [Related]

  • 6. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA, ESS40011 (STARR) Study Team.
    BMC Infect Dis; 2003 Jun 10; 3():10. PubMed ID: 12795812
    [Abstract] [Full Text] [Related]

  • 7. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
    Bongiovanni M, Bini T, Chiesa E, Cicconi P, Adorni F, Monforte d'Arminio A.
    Antiviral Res; 2004 Apr 10; 62(1):53-6. PubMed ID: 15026202
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 10; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 9. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M, van der Ende ME.
    Antivir Ther; 2003 Oct 10; 8(5):455-61. PubMed ID: 14640393
    [Abstract] [Full Text] [Related]

  • 10. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X, Podzamczer D, Moral I, Roset M, Arnaiz JA, Loncà M, Casiró A, Rosón B, Gatell JM, BestQol Study Group.
    Antivir Ther; 2004 Dec 10; 9(6):979-85. PubMed ID: 15651756
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, Study Team.
    HIV Med; 2007 Nov 10; 8(8):529-35. PubMed ID: 17944686
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May 10; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F, ANRS 109 VISTA Study Group.
    Antivir Ther; 2006 May 10; 11(7):889-99. PubMed ID: 17302251
    [Abstract] [Full Text] [Related]

  • 15. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May 10; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group.
    Antivir Ther; 2008 May 10; 13(3):375-80. PubMed ID: 18572750
    [Abstract] [Full Text] [Related]

  • 18. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
    Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D'Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, Gatell JM, BEST Study Team.
    AIDS; 2003 Apr 11; 17(6):831-40. PubMed ID: 12660530
    [Abstract] [Full Text] [Related]

  • 19. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E, Dreezen C, Desmet P, Smets E, Fransen K, Vandercam B, Pelgrom J, Clumeck N, Colebunder R.
    Antivir Ther; 2001 Dec 11; 6(4):255-62. PubMed ID: 11878407
    [Abstract] [Full Text] [Related]

  • 20. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
    Cressey TR, Leenasirimakul P, Jourdain G, Tod M, Sukrakanchana PO, Kunkeaw S, Puttimit C, Lallemant M.
    J Antimicrob Chemother; 2005 Jun 11; 55(6):1041-4. PubMed ID: 15883177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.